In-article:

PREDILIFE: LÉMAN HOSPITALS COMMIT TO BREAST CANCER PREVENTION WITH THE MAMMORISK(R) TEST – 03/14/2022 at 07:00


LÉMAN HOSPITALS COMMIT TO BREAST CANCER PREVENTION WITH THE MAMMORISK® TEST

Paris, France, March 14, 2022, 07:00 CET – PREDILIFE (Euronext Growth: ALPRE FR0010169920), a specialist in innovative pathology risk prediction solutions for personalized medicine, announces the signature of a collaboration with Hôpitaux du Léman, an establishment in Groupe Hospitalier Léman-Mont-Blanc, with the launch of a study to deploy the breast cancer prevention assessment in clinical practice.

The most common cancer in women, breast cancer is generally a disease with a good prognosis when diagnosed early. This is the challenge of the screening strategies put in place by the health authorities and/or the medical profession as a whole. Recent advances in the field of genetics and imaging allow earlier management and offer the opportunity to adapt patient follow-up to make it more effective.

The MammoRisk® predictive test, developed in collaboration with the Institut Gustave Roussy in Paris, and the Breast Cancer Screening Consortium in the United States, is a test integrating the main risk factors for breast cancer. It allows the doctor to assess, in women from the age of 40, the probability of developing invasive breast cancer within 5 years, and to offer them a screening and follow-up program adapted to their individual risk.

The Léman Hospitals, supported by the Breasts Léman Avenir Association, are the first Public Establishment to engage in a breast cancer prevention approach by opening a risk consultation using the Mammorisk® test.

“I am very happy with this initiative by Hôpitaux du Léman. It is the first Public Establishment to initiate such a program. This will make it possible to deploy these prediction tests to all women and thus to structurally reduce advanced stage breast cancers.”

says Stéphane Ragusa, CEO and Founder of PREDILIFE.

contacts

Investor Relations

PREDILIFE

Stephane Ragusa

Chairman and CEO

[email protected]

Press relations

CAPVALUE

01 80 81 50 00

[email protected]

About HOSPITALS DU LÉMAN

The HOSPITALS OF LÉMAN are one of the 7 Public Establishments that make up the Groupement Hospitalier de Territoire Léman-Mont-Blanc. An ambitious shared medical project and partnerships with the Centers Hospitaliers de Grenoble and Lyon make Hôpitaux du Léman, which manages an operating budget of 130 million euros for 36,000 hospitalized patients each year, a leading player in this region.

To know more :

www.hopitauxduleman.fr

About PREDILIFE

PREDILIFE is a pioneer in the design and development of predictive tests, allowing each person to define their risk profile for the occurrence of serious diseases. It uses artificial intelligence methods applied to clinical, genetic and imaging medical data. PREDILIFE markets in Europe and internationally Mammorisk®, as well as assessments for the prediction of the main pathologies.

To know more :

www.predilife.com


This post has the “🔒 Actusnews SECURITY MASTER” service.


– SECURITY MASTER Key:

lGpqZ8VraGaayHBwl5tpapKUb2yTmWOXm5bHmmFplJnGZ2pkymmWb5bIZnBkmmlt

– To check this key:

https://www.security-master-key.com.



Regulated information:


Inside information:

– Other press releases


Full and original press release in PDF format:

https://www.actusnews.com/news/73547-cphopitauxdulemanvf.pdf

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com



Source link -86